Biliary System Flashcards
Labs elevated and/or positive w/ PBC (3)
AMA
ALP
IgM
PBC treatment
ursodeoxycholic acid 13-15 mg/kg/day
PSC MRCP findings
beaded bile ducts (strictures and dilations)
PSC biopsy findings
onion-skin fibrosis
Imaging/procedural monitoring for PSC (2)
annual MRCP or US
colonoscopy every 1-2 yrs (high UC risk)
Pain control for cholelithiasis
ketorolac 30 mg IV
Utility of GGT
confirming biliary source of elevated ALP
Types of gallstones (2)
cholesterol (most common)
pigment (hemolysis, cirrhosis)
Causes of pigmented gallstones (2)
hemolysis
cirrhosis
Gold standard diagnosis for cholelithiasis
ultrasound
PBC pathophysiology
progressive destruction of intrahepatic ducts - leads to fibrosis and cholestasis
Antibody associated w/ PBC
anti-mitochondrial (AMA)
Liver enzyme primarily elevated in PBC
alk phos
PBC first-line treatment
ursodeoxycholic acid 13-15 mg/kd/day divided into 2 doses
Chemotherapy for cholangiocarcinoma (2)
gemcitabine
cisplatin
PSC pathophysiology
inflammation and fibrosis of the bile ducts, both intrahepatic AND extrahepatic
Timeframe for surgery in acute cholecystitis
72 hours
Typical GGT level in cholestasis
elevated
Gallbladder polyp size where cholecystectomy is indicated
> 1 cm or symptomatic
Causes of GGT elevation (4)
hepatitis
alcohol use disorder
cirrhosis
biliary disease
Mutation in Gilbert’s syndrome
UGT1A1 gene
Yearly monitoring for PSC (2)
MRCP
CA 19-9